Rocatinlimab
AMG 451 / KHK4083Lead anti-OX40 in atopic dermatitis. Three-way race with Sanofi/Amlitelimab and AbbVie/Telazorlimab.
Emerging drug — Phase 3 readout — POSITIVE
✓ Won · Read out 2024-09-25ROCKET-HORIZON met co-primary endpoints (vIGA-AD 19.3% vs 6.6% placebo, p<0.001; EASI-75 32.8% vs 13.7%). IGNITE topline Mar 2025 also positive (EASI-75 42.3% vs placebo, p<0.001 at higher dose). ASCEND long-term extension Sep 2025 confirms safety profile. Lancet publication 2025-2026.
Next remaining catalyst
AwaitingA positive readout makes TNFRSF4 a validated target for the first time. Hover the badge above for what the confidence level means.
What does it do?
TNFRSF4 — OX40 (Tumor Necrosis Factor Receptor Superfamily 4)
Modality: monoclonal antibody (anti-OX40, depleting)
Program: ROCKET-AD
The 8 Phase 3 trials
| NCT ID | Indication | N | Status | Started | Primary completion | Readout |
|---|---|---|---|---|---|---|
| NCT05398445 | Atopic Dermatitis | 769 | COMPLETED | 2022-05-31 | 2024-11-28 (actual) | Awaiting |
| NCT05651711 | Atopic Dermatitis | 726 | COMPLETED | 2022-12-14 | 2024-06-05 (actual) | Awaiting |
| NCT05633355 | Atopic Dermatitis | 187 | COMPLETED | 2023-01-30 | 2025-07-31 (actual) | Awaiting |
| NCT05724199 | Atopic Dermatitis | 746 | COMPLETED | 2023-02-21 | 2024-09-15 (actual) | Awaiting |
| NCT05704738 | Atopic Dermatitis | 532 | COMPLETED | 2023-04-20 | 2025-02-27 (actual) | Awaiting |
| NCT05882877 | Atopic Dermatitis | 2,621 | ACTIVE_NOT_RECRUITING | 2023-05-31 | 2027-06-30 | Fresh est. |
| NCT05899816 | Atopic Dermatitis; Moderate-to-severe Atopic Dermatitis | 221 | COMPLETED | 2023-06-07 | 2024-08-26 (actual) | Awaiting |
| NCT06527404 | Prurigo Nodularis | 469 | ACTIVE_NOT_RECRUITING | 2024-07-18 | 2026-10-28 | Fresh est. |
What deals have been done?
| Year | Type | Counterparty | Value |
|---|---|---|---|
| 2021 | license | Kyowa Kirin | $1.3B (option exercise + milestones) |
What's the case for and against?
✓ What's working in its favor
- Phase 2b atopic dermatitis: ~50% EASI-75 vs placebo (n=274)
- Largest enrollment in dataset for emerging-target drug (n=2,621)
Who else is racing? — 2 other assets at TNFRSF4
| Asset | Sponsor | Status |
|---|---|---|
| Amlitelimab | Sanofi/Kymab | P3 atopic dermatitis (COAST-1, COAST-2) |
| Telazorlimab | AbbVie | P2 atopic dermatitis |
Source: TheraRadar atomic trial table (built 2026-04-28 from ClinicalTrials.gov v2 API). Trial-target mapping validated via Gemini 2.0 + Gemini 3.1 Lite + Claude Haiku 4.5 multi-LLM consensus, with Claude Sonnet 4.6 arbitration. BD context curated by hand from public disclosures.